A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.02.062
Abstract: BACKGROUND Secukinumab is a first-in-class IL-17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in Phase III studies. OBJECTIVES To evaluate the effectiveness of secukinumab in daily clinical practice and to understand… read more here.
Keywords: prospective multi; 158 patients; multi center; center study ... See more keywords